Abstract
Given the fact that the forecasts show the continuation of the occurrence of cases of coronavirus disease 19 (COVID-19) and the evolution towards Long COVID, the identification of a chemoprophylactic agent is of major importance. For this purpose, we propose SLU-PP-332, an estrogen-related receptor alpha (ERRα) agonist, which, besides the effect of stimulating mitochondrial biogenesis, it is possible to inhibit angiotensin-converting enzyme 2 (ACE2), stimulate immunity, inhibit pro-inflammatory cytokines, reduce the number of entry points into cells of SARS-CoV-2 at the level of adipose tissue through fibronectin type III domain-containing protein 5 (FNDC5), and to protect vascular endothelium from oxidative stress. Considering the existence of experimental models for COVID-19, it is possible to test these effects, as well as the possibility of combining the administration of SLU-PP-332 with the performance of moderate-intensity physical exercises, this in order to accelerate the adaptation to exercise of the mitochondria of the whole body, a supposed prophylactic factor for severe forms of COVID-19.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
